Investor Presentaiton

FY 2024 : Sales outlook retained 1 Sales drivers CDMO: Revenue expansion of base pipeline projects and 2H Animal health contract supplies kick-off Generics¹: Growth in existing and new CMO contracts (Diabetic & CV portfolio) across key markets, Key product approvals and better visibility in ARV business Bio: Ramp-up of new capacity implemented Completion of Large Purchase order in FY2023 Pricing Headwinds in ARV APIs and FDF ■ Year of Consolidation Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 LAURUS Labs Knowledge. Innovation. Excellence 1 Including API and Formulation 29 29

View entire presentation